Polyamines are ubiquitous organic cations that play critical but still not completely defined roles in key cellular processes such as cell proliferation, differentiation, and nucleic acid synthesis (6, 17, 19, 34, 35, 59, 65) . Since polyamines are especially important to rapidly growing cells, the polyamine pathway has been targeted in a multiplicity of antineoplastic and antiparasitic drug regimens. Most notably, DL-␣-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first enzyme in the polyamine biosynthesis pathway, is effectively curative against late-stage African sleeping sickness caused by the protozoan parasite Trypanosoma brucei gambiense (3, 14, 57) . Interestingly, the selectivity of DFMO for the metabolic machinery of the parasite is not brought about by differential sensitivities of the parasite and human ODC enzymes to inactivation by DFMO but is rather due to a novel mechanism involving disparities in ODC turnover rates between T. brucei and the mammalian host (22, 23) . DFMO is also active against other trypanosome species in mouse models and has proven effective against other genera of protozoan parasites including Plasmodium species (2, 12, 13) , Giardia (24) , and Leishmania (44, 52) . Other inhibitors of enzymes involved in polyamine biosynthesis have also shown efficacy against parasites. For instance, 5Ј-{[(Z)-4-amino-2-butenyl]methylamino}-5Ј-deoxyadenosine (MDL73811), an inhibitor of S-adenosylmethionine decarboxylase (ADOMETDC) whose product provides the aminopropyl moieties for spermidine and spermine synthesis, is effective at eradicating T. brucei infections in rodent models (4) . Many other polyamine synthesis inhibitors and antimetabolites have been synthesized, but the mechanisms of action of these compounds are mostly unknown and not easily ascertained (6, 17, 19, 34, 35, 59, 65) .
Due to the absence of effective vaccines, chemotherapy has offered the only avenue for treating and preventing parasitic diseases. Unfortunately, the current arsenal of antiparasitic drugs is far from ideal, mainly because the drugs exhibit cytotoxicity due to a lack of target specificity. Thus, the need for more selective and efficacious drugs to treat or prevent parasitic diseases is imperative. The success of DFMO against African trypanosomiasis has stimulated considerable interest in the polyamine pathways of parasites and in evaluating other biosynthesis inhibitors as well as polyamine analogs as potential antiparasitic drugs.
Leishmania donovani, a diploid protozoan parasite that is closely related to T. brucei, is the causative agent of visceral leishmaniasis, a devastating and invariably fatal disease if untreated. The parasite exhibits a digenetic life cycle, with the extracellular promastigote residing in the sandfly vector and the intracellular amastigote form inhabiting the phagolysosome of mammalian macrophages. The polyamine biosynthetic pathway of L. donovani consists of three enzymes: ODC, ADOMETDC, and spermidine synthase (SPDSYN). There is no spermine synthase encoded in the leishmanial genome (L. major GeneDB), and the parasites lack spermine (36), a major polyamine in the mammalian host. The polyamine auxotrophy exhibited by L. donovani promastigotes in which both copies of ODC, ADOMETDC, or SPDSYN have been genetically eliminated has established the essential roles of these enzymes in parasite viability and proliferation (36, 53, 54) . Moreover, the phenotypic characterization of these null mutants revealed significant differences between the polyamine pathways of the parasite and humans (36, 53, 54) , implying that these enzymes in Leishmania and possibly other parasites have potential as targets for antiparasitic drugs (5, 16, 21, 31, 51) .
Although many polyamine and ornithine analogs display antiparasitic effects, their mechanisms of action have not been demonstrated, with the single exception of DFMO (22, 23) . In principle, polyamine analogs could inhibit the polyamine biosynthetic pathway, displace polyamines from performing their functions, or disrupt unrelated cellular processes. In a previous study, L. donovani ADOMETDC was overexpressed in L. donovani promastigotes, and this overexpression conferred profound resistance to MDL73811 but not to pentamidine, berenil, and mitoguazone (MGBG) (54) . Those studies suggested that polyamine biosynthetic enzyme-overproducing strains could be useful in identifying whether various polyamine analogs exert their cytotoxicity predominantly by inhibiting specific enzymes of the polyamine biosynthetic pathway. We now report the generation and characterization of L. donovani lines that overexpress ODC and SPDSYN. The polyamine biosynthetic enzyme-overproducing strains were then exploited to ascertain the mode of action of a battery of polyamine analogs in L. donovani promastigotes. Cell culture. Wild-type L. donovani clone DI700, originally derived from the 1S Sudanese strain, was the recipient strain for transfections. Parasites were cultivated in DME-L, a completely defined Dulbecco's modified Eagle-based medium that was specifically developed for growing Leishmania promastigotes (33) . Parasites grown in the presence of putrescine or spermidine were maintained in a modified DME-L medium, DME-L-CS, in which the bovine serum albumin component of DME-L was replaced with 10% chicken serum to avert polyamine oxidase-mediated polyamine toxicity (37) . Transfected parasites were maintained in 100 g/ml G418 but were cultured in media without G418 for growth experiments. To assess the effects of drugs on parasite growth, 1.0-ml volumes in 24-well plates were seeded at 1.0 ϫ 10 5 parasites/ml, and parasites were enumerated after 5 days by Coulter Counter model ZF as described previously (36, 37) .
MATERIALS AND METHODS

Materials
Overexpression vectors. The construction of the ADOMETDC overexpression vector pXNEO[ADOMETDC] has been described previously (54) . To construct the ODC overexpression vector pSNBR[ODC], a 15-kb HindIII-EcoRI ODCcontaining fragment from the ODC-5L1 cosmid (36) was inserted into the polylinker site of the pSNBR vector. The SPDSYN overexpression vector pSNAR [SPDSYN] was created by cloning a 4.5-kb BamHI-HindIII genomic fragment containing the SPDSYN coding region (53) into the polylinker site of pSNAR.
Transfections. The construction of the ADOMETDC-overproducing L. donovani strain (DI700[pADOMETDC]) has been described previously (54 [SPDSYN] , respectively, using previously reported electroporation conditions (36) . Parasites harboring episomal constructs were selected with 100 g/ml G418.
Immunoblotting. The sources of rabbit polyclonal antibodies to purified L. donovani ODC, SPDSYN, and ADOMETDC have been reported previously (36, 53, 54) . Promastigote lysates were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (38, 56) , blotted onto nitrocellulose membranes using a Semi-Dry Electrophoresis Transfer Cell (Bio-Rad), and subjected to Western blot analysis according to standard protocols (56) . Band intensities were quantitated by densitometry using an Epson Perfection 2400 PHOTO scanner (Epson America Inc., Long Beach, CA), and the intensity of each band was measured by the Alpha Ease FC software program (Alpha Innotech Corp., San Leandro, CA).
Polyamine pool analysis. Polyamine pools were measured as reported previously (54) . Briefly, wild-type and transfected parasites were grown for 3 days, and 1 ϫ 10 7 parasites were harvested in the mid-logarithmic growth phase. Acidsoluble extracts were analyzed for putrescine and spermidine contents by reverse-phase high-performance liquid chromatography. VOL. 51, 2007 LEISHMANIA POLYAMINE BIOSYNTHETIC ENZYME OVERPRODUCERS 439 blot analysis confirmed the presence of the plasmids in the selected parasites (data not shown). These analyses revealed that the transfectants harbored several hundred copies of the corresponding episome (data not shown). The construction of an ADOMETDC expression plasmid, transfection, and selection of episome-bearing parasites have been described previously (54) . Phenotypic characterization of polyamine biosynthetic enzyme overproducer strains. None of the three L. donovani strains transfected with plasmids encoding polyamine biosynthetic enzymes exhibited any growth defects, and their doubling times were equivalent to that of wild-type parasites (data not shown). Western blot analysis revealed robust overexpression of ODC, SPDSYN, and ADOMETDC in the relevant DI700[pODC], DI700[pSPDSYN], and DI700[pADOMETDC] transfectants, respectively (Fig. 1) . Quantification of enzyme expression by densitometry indicated that levels of ODC, SPDSYN, and ADOMETDC in lysates from the transfectants were elevated ϳ46-fold, ϳ60-fold, and ϳ25-fold compared to the nontransfected parental cell extracts. Levels of the other polyamine biosynthesis enzymes in the DI700[pODC], DI700[pSPDSYN], and DI700[pADOMETDC] transfectants were virtually unchanged compared to the wild-type line (Fig. 2) .
RESULTS
Generation
The consequences of increased enzyme levels on intracellular polyamine pools were also examined (Fig. 3) . The DI700[pODC] line exhibited a sevenfold increase in putrescine pools and a twofold increase in spermidine levels compared to its wild-type counterpart, while a threefold augmentation in putrescine levels was observed in the DI700[pSPDSYN] transfectant. DI700[pADOMETDC] ADOMETDC overproducers exhibited putrescine and spermidine levels similar to those of wild-type parasites.
Effect of DFMO, MDL73811, and n-butylamine on wildtype and overproducer strains. DFMO, MDL73811, and n-butylamine are known to inhibit the enzymes ODC, ADOMETDC, and SPDSYN, respectively, in vitro (15, 20, 25, 26, 50) . Thus, it was conjectured that these agents will also specifically target these enzymes in vivo and that augmented levels of ODC, ADOMETDC, and SPDSYN will protect the parasites from the toxicity of the compounds. As shown in Table 1 , ODC, ADOMETDC, and SPDSYN overproducer strains were markedly resistant to DFMO, MDL73811, and n-butylamine, respectively, compared to wild-type parasites. Likewise, putrescine supplementation protected wild-type parasites from DFMO toxicity, and spermidine supplementation shielded the parasites from the inhibitory effects of MDL73811 and n-butylamine. It should be noted that the ODC overproducer also exhibited an increased resistance to n-butylamine. Thus, n-butylamine may not be a specific inhibitor of SPDSYN but may also act on ODC. These assays were performed as proof of concept that polyamine biosynthetic enzyme overproducer strains can be exploited to determine target specificities of synthetic polyamine analogs. Effect of pentamidine, berenil, and MGBG on wild-type and polyamine biosynthetic enzyme overproducer strains. Pentamidine, berenil, and MGBG have previously been postulated to exert their toxicity by inhibiting the polyamine biosynthetic pathway (7, 11, 45) . However, other cellular targets have also been proposed (8, 9, 41, 43, 62) . To determine whether these compounds specifically target the polyamine biosynthetic enzymes or interact with other cellular functions in intact organisms, the proliferation of wild-type and overproducer strains in the presence of these drugs was compared. The 50% effective concentration (EC 50 ) values for wild-type parasites, parasites supplemented with putrescine or spermidine, and ODC, ADOMETDC and SPDSYN overproducer strains were nearly equivalent ( Table 2 ). This result suggests that although pentamidine, berenil, and MGBG may inhibit polyamine biosynthetic enzymes in vivo, their primary cellular toxicity is mediated through other cellular interactions.
Screening of polyamine analogs. To assess whether the polyamine overproducer lines could be exploited as a cell-based screen to evaluate the cellular targets of synthetic polyamine analogs, a pilot test was performed with 25 compounds provided by Cellgate on wild-type L. donovani promastigotes. Of the 25 Cellgate compounds, 8 were cytotoxic and inhibited growth of the parasite by Ͼ90% at a concentration of 100 M, 4 inhibited growth by 25 to 75%, and the remainder exhibited no inhibitory effect or even resulted in a higher cell density than the no-drug controls ( Table 3 ). The potencies of some of the most cytotoxic reagents were then further evaluated at lower doses. The effective concentrations of polyamine analogs CGC-11235, CGC-11237, CGC-11211, CGC-11227, CGC-11226, a Wild-type parasites were incubated without drug or in a 100 M concentration of each test compound. Proliferation of wild-type parasites was enumerated after 5 days. Growth in medium without drug was taken as 100% growth. Each percent value is the mean and standard deviation of two independent experiments. Some compounds were evaluated at a range of concentrations from 0.001 to 1000 M to determine the EC 50 (Fig. 4A and C) . In contrast, EC 50 values of 9 M for CGC-11159 were obtained for wild-type L. donovani and the DI700[pODC] overproducer, whereas an EC 50 value of 50 M was calculated for the DI700[pSPDSYN] strain.
DISCUSSION
The critical role that polyamines play in cell proliferation, differentiation, and development (6, 17, 19, 34, 35, 59, 65) coupled with the success of DFMO in the treatment of African trypanosomiasis (3, 14, 57) have stimulated considerable interest in the polyamine pathway as a target for potential antiparasitic chemotherapies. Each of the three enzymes of the leishmanial polyamine biosynthetic pathway has been genetically validated as a prospective drug target via the creation of ⌬odc, ⌬spdsyn, and ⌬adometdc knockouts in L. donovani by doubletargeted gene replacement that all exhibited polyamine auxotrophy (36, 53, 54) . Leishmania promastigotes and axenic amastigotes (10) are able to transport polyamines, and a polyamine permease has been identified at the molecular level in Leishmania major (28) . It is unknown, however, whether Leishmania in the amastigote form is capable of scavenging polyamines from the host phagolysosome.
Despite the plethora of drugs that have been reported to target polyamine biosynthesis in protozoan parasites, there is little evidence, other than that obtained with DFMO (22, 23) , that establishes the polyamine biosynthetic machinery as the true primary intracellular target of these antiparasitic agents. Polyamine analogs, antimetabolites, or related drugs could also be cytotoxic by displacing natural polyamines or by disrupting unrelated cellular functions. In order to establish whether polyamine analogs actually target the pathway, we have created individual transgenic L. donovani strains that have been transfected with episomal constructs harboring each one of the polyamine biosynthesis genes and that consequently overproduce the encoded protein by 25-to 60-fold compared to wild-type parasites (Fig. 1) . Each of these transfectant lines, DI700
[pODC], DI700[pSPDSYN], and DI700 [pADOMETDC] , is theoretically isogeneic with their wild-type parent except for the episomal sequences, thereby facilitating target identification through phenotypic discrepancies. Our reverse genetic stratagem clearly indicates that the primary intracellular targets of DFMO and MDL73811 are ODC and ADOMETDC, respectively. Conversely, the cellular toxicities of pentamidine, berenil, and MGBG, all drugs postulated to inhibit polyamine metabolism (7, 11, 45) , do not appear to be mediated through the targeting of the polyamine biosynthetic machinery in L. donovani promastigotes since the cytotoxicity profiles of the overproducer strains are virtually identical to those of wildtype parasites. These results reinforce previous observations that pentamidine, berenil, and MGBG have other cellular targets (8, 9, 41, 62) . It should be noted that the generation of some ODC and any ADOMETDC or SPDSYN overexpressor strains has been difficult to achieve in mammalian cell lines, presumably due to VOL. 51, 2007 LEISHMANIA POLYAMINE BIOSYNTHETIC ENZYME OVERPRODUCERS 443 their sensitivity to internal polyamine levels (32, 42, 46, 60) . An increase in polyamines is often associated with cancer or apoptosis, depending on the cell and tissue type (59, 63, 64, 66, 68, 70) . Mammalian ODC and ADOMETDC are subjected to an intricate regulatory network that includes the regulation of expression and degradation (18, 48, 49, 58, 61, 67) . Indeed, ODC and ADOMETDC are among the most labile mammalian proteins known (29, 30, 47, 69) . Intriguingly, the leishmanial polyamine biosynthetic enzymes are stable proteins that show no signs of degradation after 24 h (27, 54), suggesting that different regulatory mechanisms maintain a stable intracellular polyamine level in these parasites. Thus, it may not be surprising that L. donovani strains that robustly overproduce ODC, SPDSYN, or ADOMETDC but that maintained relatively stable polyamine levels in all three cell lines could be generated. Our inhibition studies with DFMO, MDL73811, and nbutylamine confirm the proof of principle that polyamine biosynthetic enzyme overproducer strains can be exploited to identify compounds that specifically inhibit the polyamine pathway enzymes in vivo. A pilot screen in which 25 polyamine analogs were tested against the overproducer strains ascertained that the polyamine biosynthetic enzyme-overproducing L. donovani strain can serve as a foundation for a cell-based screening assay to identify specific inhibitors of the polyamine biosynthetic enzymes. While this assay was performed with the extracellular promastigote form of the parasite, it can be extended to evaluate the effects of polyamine analogs on axenic amastigotes and intracellular amastigotes in macrophages as well. Furthermore, this screening assay can presumably be optimized by transfecting wild-type parasites and overproducer strains with a luciferase expression construct, thereby enabling the rapid and automated detection of bioluminescent signals as proliferation indicators (1, 39, 55) . A battery of polyamine analogs has already been synthesized by industry and academia as antiproliferative agents, and a systematic testing of these compounds as antiparasitic agents is greatly overdue and desirable in view of the dire need of new therapeutic agents against leishmaniasis. Significantly, our approach using polyamine biosynthetic enzyme-overproducing strains presents a generally applicable strategy that can be used to screen for specific inhibitors of any protein that can be overproduced in Leishmania. In addition, the Leishmania system may provide a powerful tool for the heterologous expression of foreign genes that would enable direct target comparisons between parasites and the mammalian host. For example, our group has established that both human ADOMETDC and SPDSYN are functional in Leishmania, since transfection with their cDNAs rescued ⌬adometdc and ⌬spdsyn parasites, respectively, from polyamine auxotrophy (data not shown). Thus, this system has the potential to identify polyamine analogs that specifically target the parasite enzyme and not the human counterpart, thereby creating a therapeutic paradigm that offers selectivity.
